Maxim Group analyst Jason McCarthy initiated coverage on Kite Pharma Inc (NASDAQ:KITE) with a Buy rating and a price target of $87, which represents …
Kite Pharma Inc (NASDAQ:KITE), announced clinical biomarker data from patients with relapsed/refractory B cell malignancies treated with anti-CD19 chimeric antigen receptor (CAR) T-cell therapy …
In a research report issued today, Canaccord Genuity analyst John Newman reiterated a Buy rating on Kite Pharma Inc (NASDAQ:KITE) with a price …
Kite Pharma Inc (NASDAQ:KITE) has been reiterated as a Buy at Canaccord Genuity by research analyst John Newman. The analyst reiterated a Buy rating on …
